Brittany Grammas, PharmD Candidate

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

New trials explore glucagon-like peptide-1 receptor agonists for alcohol, nicotine use disorder, and smoking cessation.